1. Introduction {#s0005}
===============

There is increasing interest in the investigation of neuroanatomical alterations in clinically healthy individuals at high risk for psychosis and patients in the early stages of the disorder, in order to develop potential biomarkers for early diagnosis. The vast majority of the studies have examined neuroanatomical alterations by measuring grey matter volume (GMV) using voxel-based morphometry (VBM) ([@bb0115; @bb0155; @bb0140; @bb0045; @bb0040; @bb0130; @bb0200; @bb0125]); in addition, a smaller number of studies have measured cortical thickness(CT) using a cortical surface-based approach ([@bb0190; @bb0055; @bb0165; @bb0215; @bb0105]). With regard to patients in the early stages of psychosis, consistent GMV and CT alterations have been reported in medial and lateral temporal regions and, to a lesser extent, dorso-lateral prefrontal and cingulate regions ([@bb0115; @bb0190; @bb0140; @bb0055; @bb0200; @bb0165; @bb0030; @bb0105]).With regard to individuals at high risk of developing the disorder, GVM and CT alterations have been reported in frontal, cingulate and temporal regions ([@bb0045; @bb0200; @bb0215; @bb0105]).

The studies published so far have typically focused on either grey matter volume or cortical thickness separately; however these two measurements reflect complementary aspects of neuroanatomy and may provide different sensitivity depending on the pathophysiological process under investigation. More specifically, the analysis of cortical thickness targets the presence of specific cortical atrophy, whereas the analysis of grey matter volume returns a mixed measure which depends on local cortical thickness as well as cortical folding and gyrification (i.e. cortical surface area) ([@bb0095]). Thus, when used in combination, GMV and CT measurements provide more comprehensive information about the underlying pathophysiological changes. At present, only two studies have examined both GMV and CT in the early phases of psychosis ([@bb0185; @bb0175]); these have reported discrepant findings as to whether GMV and CT alterations are expressed in similar or different areas. More specifically, [@bb0175] observed reduced CT and GMV in prefrontal and temporal regions in patients with a first episode of psychosis ([@bb0175]). In contrast, Voets and colleagues showed widespread but focally distinct patterns of CT and GMV alterations in adolescents with early-onset schizophrenia ([@bb0185]). Moreover, to the best of our knowledge, no previous study has examined both aspects of neuroanatomy in both patients with a first episode of psychosis (FEP) and individuals at high risk of developing the disorder.

In the present study we therefore employed both voxel-based CT (VBCT; [@bb0095]) and voxel-based morphometry (VBM; [@bb0015]) to investigate neuroanatomical alterations in patients with a first episode of psychosis (FEP) and individuals with an at risk mental state (ARMS) for psychosis relative to healthy controls. These two analytical techniques were chosen because they use the same pre-processing and registration procedures and allow the identification of voxel-level GMV and CT alterations within the same volumetric space, thereby minimizing any potential confounding methodological differences ([@bb0100; @bb0135]). Our main aim was to examine whether GMV and CT alterations precede the clinical manifestation of psychosis and therefore represent neuroanatomical markers of vulnerability to this disorder. We hypothesized that (1) both individuals with an ARMS and FEP patients would present with common cortical alterations in a network of interest comprising frontal, temporal and cingulate regions and (2) FEP patients would show more pronounced alterations compared to ARMS individuals in these regions. Our secondary aim was to examine whether VBM and VBCT would reveal distinct or similar alterations within our network of interest. We expected that the two techniques would reveal focally distinct GMV and CT effects, reflecting different underlying pathophysiological processes.

2. Methods {#s0010}
==========

2.1. Participants {#s0015}
-----------------

The study was approved by the local Research Ethics Committee. Participants gave written informed consent after a full description of the aims and design of the study. The following exclusion criteria applied to all participants: (i) a history of neurological disorders; (ii) head trauma resulting in loss of consciousness for over 1 h; (iii) evidence of substance abuse and dependence disorder according to the DSM-IV criteria and (iv) suspected or confirmed pregnancy. All but one subject in each group were right-handed, while English was the first and native language of all the participants in this study.

### 2.1.1. First episode psychosis (FEP) group {#s0020}

Twenty-six subjects were recruited from early intervention services within the South London and Maudsley National Health Trust. All individuals presented for the first time to the local psychiatric services and met ICD-10 criteria schizophreniform psychosis ([@bb7000]). One patient only was medication naive while the remaining had been treated for a mean of 155 days at chlorpromazine equivalent mean dose of 242 mg/day. See [Table 1](#t0005){ref-type="table"} for the demographic characteristics of this sample.

### 2.1.2. At Risk Mental State (ARMS) group {#s0025}

Twenty-one individuals meeting the Personal Assessment and Crisis Evaluation (PACE) criteria for the ARMS ([@bb0205]) on the basis of the Comprehensive Assessment for the ARMS (CAARMS; [@bb9000]) were recruited through the Outreach and Support in South London (OASIS) service. Two ARMS participants only had been treated with antipsychotic medication (at chlorpromazine equivalent mean dose of 76.68 mg/day over the 18 months prior the MRI scan) while the remaining 17 subjects were medication naive. See [Table 1](#t0005){ref-type="table"} for the demographic characteristics of this sample.

### 2.1.3. Controls {#s0030}

Twenty-four healthy volunteers were recruited by advertisement from the local community. Additional exclusion criteria included (i) a current or past history of psychiatric illness, and (ii) the presence of psychosis in first-degree relatives. See [Table 1](#t0005){ref-type="table"} for the demographic characteristics of this sample.

2.2. Clinical assessment {#s0035}
------------------------

The Positive and Negative Syndrome Scale (PANSS; [@bb0110]) was used to assess the presence and severity of symptoms in the clinical groups on the day of scanning while the Prodromal Questionnaire ([@bb6000]) was used to confirm the absence of any psychotic syndromes in healthy volunteers. The general premorbid intellectual function was estimated using the reading subtest of the Wide Range Achievement (WRAT-R; [@bb5000]). The clinical characteristics for the three groups are reported in [Table 1](#t0005){ref-type="table"}.

2.3. MRI analysis {#s0040}
-----------------

### 2.3.1. MRI data acquisition {#s0045}

T1-weighted images were acquired on a 3.0 T GE Signa system (GE Medical Systems, Milwaukee), at the Maudsley Hospital, London, using a fast Spoiled Gradient Recalled (FSPGR) in Steady State sequence. Image acquisition parameters were: 1.1 mm thick coronal slices, TR/TE/TI = 28.32/7.08/450 ms, 20˚ flip angle and field of view 21 cm. For each subject, 196 coronal partitions were acquired with an image matrix of 256 × 256 (Read × Phase) providing whole-brain anatomical data with an anisotropic spatial resolution of 1.09 × 1.09 × 1.1 mm^3^.

### 2.3.2. MRI data processing {#s0050}

The unified segmentation procedure ([@bb0020]) implemented in SPM8 (<http://www.fil.ion.ucl.ac.uk/spm>) was used to segment all the images into grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) partitions.

#### 2.3.2.1. Creation of voxel-based grey matter volume maps {#s0055}

A fast diffeomorphic image registration algorithm (DARTEL) was used to warp the GM partitions into a new study-specific reference space with an isotropic spatial resolution of 1.5 mm^3^ ([@bb0010; @bb0025; @bb0005]). The warped GM partitions were then affine transformed into the MNI space. An additional 'modulation' step ([@bb0075]) was used to scale the GM probability values by the Jacobian determinants of the deformations to ensure that the total amount of grey matter in each voxel was conserved after the registration. As a final step the GM probability maps were smoothed using a 6 mm FWHM Gaussian kernel.

#### 2.3.2.2. Creation of voxel-based cortical thickness maps {#s0060}

A voxel-based Laplacian method ([@bb5500; @bb0095]) was used to create a VBCT map for each subject using the GM, WM and CSF partitions created in the segmentation step. The resulting VBCT maps contained CT values within voxels identified as GM and zeros outside the cortex and were saved in the native space of the input images (1 mm^3^ resolution). Each VBCT map was warped into the new DARTEL reference space by applying the corresponding subject specific deformation field and resampled to an isotropic voxel size of 1.5 mm^3^. The warped images were then scaled by the Jacobian determinant of the deformation and smoothed with a 6 mm Gaussian kernel. The same warps, modulation and smoothing were also applied to a binary mask created from each original VBCT map. Subsequently the warped, scaled and smoothed VBCT maps were divided by the corresponding warped, scaled, and smoothed mask. The effect of this procedure was to project the Gaussian smoothing kernel applied to the warped images, into the native space of the subject while preserving the CT value over a region the size of the smoothing kernel.

### 2.3.3. Statistical analysis {#s0065}

The statistical analysis focused on a bilateral network of interest which included regions reported to show alterations of grey matter density or CT in individuals with an ARMS and patients with FEP in previous studies ([@bb0190; @bb0140; @bb0055; @bb0165; @bb0215; @bb0105]). These regions included the (1) inferior frontal gyrus (IFG), (2) middle frontal gyrus (MFG), (3) anterior and posterior cingulate cortex (ACC and PCC), (4) superior temporal gyrus (STG), (5) middle temporal gyrus (MTG) and (6) parahippocampal cortex (PHC). Using the automated anatomical labelling (AAL) system as implemented in PickAtlas toolbox ([www.nitrc.org/projects/wfu_pickatlas](http://www.nitrc.org/projects/wfu_pickatlas){#ir0020}), we constructed a mask that comprised of all these regions (total volume: 61,107 voxels). Two voxel-wise Analyses of Covariance (ANCOVAs) were performed on the GMV and CT separately; for each independent ANCOVA the GMV or the CT was entered as the dependent variable and the experimental groups as the independent and between-subject variable. The total intracranial volume (TIV) was calculated for each subject by summing together the voxel values of the original GM, WM and CSF tissue partitions. Age, gender and TIV were included as covariates of no interest to explain variance associated with these potentially confounding effects. We identified regions that showed cortical alterations in both ARMS and FEP relative to healthy controls by comparing the combined ARMS and FEP group against controls and inclusively masking (at *P* \< 0.001) the results with the individual comparisons between the ARMS group and controls and between the FEP group and controls. This procedure allowed us to identify those significant voxels in the main contrast (i.e. ARMS and FEP groups against controls) that were also significant in each of the two individual contrasts specified as mask (i.e. ARMS group against controls and FEP group against controls respectively).

Statistical inferences were made at *P* \< 0.05 after Family-Wise Error (FWE) correction for multiple comparisons. When significant differences were not detected, we tested for the presence of trends for completeness by lowering the statistical threshold to *P* \< 0.001 (uncorrected). However our discussion focuses on those differences that were significant after correction for multiple comparisons.

3. Results {#s0070}
==========

3.1. Voxel-wise differences in cortical thickness {#s0075}
-------------------------------------------------

Compared to healthy controls, individuals with an ARMS and FEP patients showed thinner cortex in the right STG (BA 42) (*P* \< 0.05, corrected; [Table 2](#t0010){ref-type="table"}; [Fig. 1](#f0005){ref-type="fig"}). In contrast, there were no regions with thicker cortex in the two clinical groups compared to the control group. When the ARMS and FEP groups were compared, the latter showed reduced CT in the right PCC (*P* \< 0.05, corrected; [Fig. 2](#f0010){ref-type="fig"}; [Table 2](#t0010){ref-type="table"}); in contrast, no areas showed an effect in the opposite direction.

3.2. Voxel-wise differences in grey matter volume {#s0080}
-------------------------------------------------

There were no regions showing grey matter increases in the two clinical groups compared to healthy controls. At a lower statistical threshold of *P* \< 0.001 (corrected), we detected trends for significant grey matter reduction common to both ARMS and FEP subjects relative to healthy controls in three brain regions ([Table 2](#t0010){ref-type="table"}). When FEP patients were compared to ARMS individuals, again no significant GMV differences were observed in either direction. At a lower statistical threshold of *P* \< 0.001 (uncorrected) we detected a trend for decreased grey matter in the left MTG and in the right STG in the FEP compared to the ARMS group ([Table 2](#t0010){ref-type="table"}). The two regions showing significant effects for CT, i.e. the right STG and PCC, did not show similar effects for GMV even when lowering the statistical threshold to *P* \< 0.05 (uncorrected).

3.3. Correlations analyses {#s0085}
--------------------------

In order to better characterize the above findings, Pearson\'s correlation coefficients were used to examine whether CT values in the right STG and right PCC were associated with PANSS scores, age or cumulative and mean doses of antipsychotic medication. A total of 28 correlation analyses were performed and no significant associations were detected (*P \<* 0.05, two tailed; [Table 3](#t0015){ref-type="table"}).

4. Discussion {#s0090}
=============

The present study used two complementary analytical techniques for assessing voxel-based GMV ([@bb0015]) and voxel-based CT ([@bb0095]) in individuals at high risk of psychosis and patients with FEP. We hypothesized that ARMS and FEP patients would present with common reductions within a network of interest comprising frontal, temporal and cingulate regions. This hypothesis was confirmed only in part, since both ARMS and FEP groups showed significant cortical thinning in the right STG (*P* \< 0.05, FWE corrected) but only trends for GMV decreases in the right ACC, right PHC and left MFG (*P* \< 0.001, uncorrected). A previous study had reported reduced CT in the right STG of patients with FEP relative to healthy controls ([@bb0080]). Our investigation replicates this finding and furthermore indicates that reduced CT in this region may be best explained in terms of enhanced vulnerability rather than the onset of the disorder. The cortical thinning of the right STG observed in the ARMS and FEP groups could be mediated by genetic influences on brain development, consistent with the observation that CT is highly heritable ([@bb0150; @bb0195]), or alternatively it could be the result of adverse life events, consistent with growing evidence of experience-dependent neuroplasticity in the human brain ([@bb0090]). All the ARMS participants included in this study had an elevated risk of developing full-blown psychosis, because they had presented with attenuated psychotic symptoms or brief limited intermittent psychotic symptoms within 3 months before study inclusion ([@bb0160; @bb0085]). In contrast, all FEP participants met ICD-10 criteria schizophreniform psychosis.

We also hypothesized that FEP patients would show more pronounced alterations compared to ARMS individuals within our network of interest; consistent with this hypothesis, we found a significant CT reduction in the FEP relative to the ARMS group in the right PCC. Thus cortical thinning in this region appears to be associated with the onset of the disorder rather than vulnerability. A previous study reported that, when using a conservative statistical threshold of *P* \< 0.05 (FWE-corrected), the only region to show a significant GMV reduction in patients with FEP relative to individuals at ultra high risk for psychosis was the middle/posterior cingulate ([@bb0200]). Our investigation expands the results of this earlier study by indicating that differences between ARMS and FEP in the PCC are likely to reflect specific cortical atrophy as opposed to variations in sulcal and gyral morphology. This conclusion is supported by a recent investigation that found widespread cortical thinning in patients with chronic schizophrenia relative to individuals at ultra high risk for the disorder in a distributed network which included the right PCC ([@bb0105]).

Our final hypothesis was that VBM and VBCT would reveal focally distinct GMV and CT alterations, reflecting different underlying pathophysiological processes. This hypothesis was confirmed in part, since VBCT revealed specific cortical atrophy in the right STG (in the FEP and ARMS groups relative to the control group) and the right PCC (in the FEP relative to the ARMS group), whereas VBM only detected trends for GMV decreases in the right ACC, left MFG and left PHC. No differences in GMV were detected in the right STG and right PCC even when lowering the statistical threshold to *P* \< 0.05 (uncorrected). One possible hypothesis is that progressive cortical atrophy in ARMS and FEP individuals might reflect an abnormal acceleration of cortical developmental processes ([@bb0180; @bb0105]). This would be consistent with the recent observation of progressive cortical thinning in the left MTG of adolescents at high risk of psychosis over time in the absence of significant differences in GMV ([@bb0215]). In order to elucidate the above hypothesis, we evaluated whether there was a significant negative correlation between CT values and age in the right STG of ARMS and FEP participants; however, we found no evidence of such an association (*p* \< 0.05). Future longitudinal studies with larger sample sizes would be needed to better evaluate the hypothesis of abnormal acceleration of cortical developmental processes in these clinical groups.

This study has three main limitations. First, the number of ARMS and FEP participants included in this investigation was relatively small (*n* = 21 and *n* = 26 respectively). However, previous studies showing significant differences in these populations included samples of comparable size ([@bb0115; @bb0190; @bb0035; @bb0200]). Furthermore, a recent analysis of effect size in classical inference has suggested that, in order to optimize the sensitivity to large effects while minimizing the risk of detecting trivial effects, the optimum sample size for a study is 16 ([@bb0060]). Nevertheless, a larger ARMS sample would have permitted to better elucidate neuroanatomical alterations associated with different levels of vulnerability to psychosis. Secondly, the present study was not designed as a longitudinal investigation and therefore we cannot provide definite information as to the rate of transition to psychosis in our ARMS group. In contrast to transition rates previously reported ([@bb0210; @bb0145]), none of the ARMS participants completing the 24 months follow-up (9 out of 21) made transition to a full-blown psychosis. This inconsistency might be due to the small and unrepresentative sample of ARMS who completed the follow-up, the impact of clinical treatment provided by early intervention services as well as the duration of the follow-up period. For instance, it has been recently proposed that longer follow-up periods are associated with higher risk of transition ([@bb0065]) and that 33% of converters have prodromal phases lasting longer than 6 years ([@bb0170]). Thirdly, the FEP patients included in the present work had been exposed to antipsychotic medication for a period of time falling within the range for which effects of medication have been previously described ([@bb0050; @bb0070; @bb0120]). Although these effects have mainly been detected in striato-limbic regions it is not possible to exclude that antipsychotic effects on brain structure had already occurred in these FEP patients. Nevertheless, it is unlikely that the alteration in the right STG observed both in the ARMS and FEP groups was driven by the impact of medication, since only two subjects with an ARMS had been medicated; furthermore, we found no evidence that cortical thickness in the right STG and right PCC was associated with antipsychotic medication.

In conclusion, cortical thinning in the right STG was present in both individuals at high risk of developing psychosis and patients with a first episode of the disorder, and therefore is likely to represent a marker of vulnerability. In contrast, the cingulate cortex showed cortical thinning in FEP patients relative to individuals at high risk, and therefore appears to be implicated in the onset of the disease. These neuroanatomical differences were expressed in terms of cortical thickness but not in terms of grey matter volume, and therefore may reflect specific cortical atrophy as opposed to variations in sulcal and gyral morphology.
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![Left. Brain regions showing cortical thinning in both ARMS and FEP participants compared to healthy controls (*P* \< 0.001uncorrected, for display purposes). T-scores are shown in the coloured bar. Right. Cortical thickness (CT) estimates in the right superior temporal cortex are shown for the three groups with the dashed lines indicating group CT means. Cortical thickness is measured in terms of mm between the inner and outer surfaces of grey matter.](gr1){#f0005}

![Left. Brain regions showing cortical thinning in FEP patients compared to ARMS participants (*P* \< 0.001 uncorrected, for display purposes). T-scores are shown in the coloured map. Right. Cortical thickness (CT) estimates in the right posterior cingulate cortex are shown for the three groups with the dashed lines indicating group CT means. Cortical thickness is measured in terms of mm between the inner and outer surfaces of grey matter.](gr2){#f0010}

###### 

Demographic and clinical characteristics of the 70 participants.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           Healthy controls\   At risk mental state\                          First episode psychosis\                        Statistics
                                                           (*n* = 23)          (*n* = 21)                                     (*n* = 26)                                      
  -------------------------------------------------------- ------------------- ---------------------------------------------- ----------------------------------------------- ----------------------------
  Age (s.d.)                                               24.2 (4.2)          22.14 (3.3)[a](#tf0005){ref-type="table-fn"}   26.08 (5.63)[a](#tf0005){ref-type="table-fn"}   *F* = 4.227*p* = 0.019

  Male/female                                              12 M:11 F           9 M:12 F                                       18 M:8 F                                        *χ*^2^ = 2.60, n.s.

  Premorbid IQ (s.d.)                                      108.8 (10.13)       101.5 (13.5)                                   101.81 (11.2)                                   *F* = 2.924 *p* = 0.06

  Antipsychotic medication                                 23 N                2 M:19 N                                       24 M:2 N[b](#tf0010){ref-type="table-fn"}       *χ*^2^ = 54.32 *p* = 0.001

  Total intracranial volume cm^3^ (s.d.)                   1537 (187)          1538(190)                                      1520(148)                                       *F* = 0.78, n.s.

                                                                                                                                                                              

  *Psychophatology scores, mean (s.d.)*                                                                                                                                       

  PANSS total                                              NA                  52.57 (9.0)                                    54.69 (14.5)                                    *t* = − 0.55, n.s.

  PANSS positive                                           NA                  12.89 (3.6)                                    13.42 (5.2)                                     *t* = − 0.378, n.s

  PANSS negative                                           NA                  14 (4.08)                                      13.96 (4.9)                                     *t* = 0.028, n.s.

  PANSS hallucinations                                     NA                  2.73 (1.3)                                     1.92 (1.23)                                     *t* = 2.09 *p* = 0.043

  PANSS delusions                                          NA                  2.68 (1.62)                                    3.00 (1.62)                                     *t* = − 0.723, n.s.

  CAARMS total                                             NA                  39.47(15.63)                                   NA                                              

                                                                                                                                                                              

  *CAARMS intake criteria for ARMS*                                                                                                                                           

  Global functioning and trait markers,\                   2 (9.5)                                                                                                            
  No. (%) of subjects                                                                                                                                                         

  Attenuated psychotic symptoms,\                          19 (90.5)                                                                                                          
  No. (%)                                                                                                                                                                     

  Brief limited intermittent psychotic symptoms, No. (%)   2 (9.5)                                                                                                            

                                                                                                                                                                              

  *Clinical outcome for ARMS (24 months)*                                                                                                                                     

  Individuals with finished follow-up, No. (%)             9 (42.8)                                                                                                           

  With transition, No. (%)                                 0                                                                                                                  

  Without transition, No. (%)                              9(42.8)                                                                                                            

  Drops-out/Unfinished follow-up, No. (%)                  12(57.2)                                                                                                           

                                                                                                                                                                              

  *Clinical outcome for FEP (12 months)*                                                                                                                                      

  Schizophrenia/ongoing psychosis, No.                                         12 (46.1)                                                                                      

  Remission/stable mental state, No.                                           13 (50)                                                                                        

  Schizoaffective disorder, No.                                                0                                                                                              

  Mood disorder, No.                                                           0                                                                                              

  Drops-out, No.                                                               1 (3.9)                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: PANSS, Positive and Negative Syndrome Scale; CAARMS, Comprehensive Assessment of At Risk Mental State; No., number.

ARMS versus FEP.

Healthy controls versus FEP.

###### 

Brain regions showing significant cortical thinning and grey matter volume reductions in ARMS and FEP individuals compared to healthy controls, and in FEP compared to ARMS individuals.

  Region                                                                    Cluster size (K)   Z      MNI coordinates          
  --------------------------------------------------------------------- --- ------------------ ------ ----------------- ------ ------
  *Cortical thickness (effects significant at P \< 0.05 corrected)*                                                            
  Controls \> ARMS & FEP                                                                                                       
   Superior temporal gyrus                                              R   88                 4.47   43                − 27   9
  ARMS \> FEP                                                                                                                  
   Posterior cingulate                                                  R   68                 4.70   4                 − 42   21
                                                                                                                               
  *Grey matter volume (trends significant at P \< 0.001 uncorrected)*                                                          
  Controls \> ARMS & FEP                                                                                                       
   Parahippocampus                                                      R   84                 4.19   24                − 15   − 31
   Middle frontal gyrus                                                 L   99                 4.19   − 38              25     33
   Anterior cingulate                                                   R   72                 4.14   3                 46     8
  ARMS \> FEP                                                                                                                  
   Middle temporal gyrus                                                L   11                 3.32   − 66              − 21   0
   Superior temporal gyrus                                              R   15                 3.30   48                − 15   − 9

R, right; L, left.

###### 

Correlations between cortical thickness measurements, clinical characteristics, medication indices and age (*P* \< 0.05, two tailed).

  --------------------------------------------------------------------------------------------------------------
                         FEP & ARMS\   FEP\          ARMS\         FEP\                                   
                         R STG (CT)\   R STG (CT)\   R STG (CT)\   R PCC (CT)\                            
                         (43 − 27 9)   (43 − 27 9)   (43 − 27 9)   (4 − 42 21)                            
  ---------------------- ------------- ------------- ------------- ------------- -------- ------ -------- ------
  PANSS positive         − .016        .918          − .148        .471          .206     .370   − .117   .570

  PANSS negative         − .156        .294          − .125        .544          − .255   .264   − .258   .203

  PANSS total            − .033        .827          − .064        .758          .036     .877   − .172   .402

  PANSS hallucinations   − .095        .524          − .380        .056          − .020   .931   − .146   .477

  PANSS delusions        − .051        .734          − .125        .544          .123     .595   − .155   .450

  Mean CPZ               --            --            − .087        .672          --       --     .246     .225

  Cumulative CPZ         --            --            .107          .604          --       --     .339     .091

  Mean age               .095          .524          .239          .240          .004     .986   .214     .237
  --------------------------------------------------------------------------------------------------------------

R STG, right Superior Temporal Gyrus; R PCC, right posterior cingulate cortex; CT, cortical thickness; ARMS, ARMS group; FEP, FEP group; FEP & ARMS, FEP and ARMS groups combined; PANSS, Positive And Negative Syndrome Scale; CPZ, chlorpromazine equivalent dose.
